Pancreatic Cancer Research

ResearcherNagoya City University Midori Municipal HospitalActive in the last 2 years

Itaru Naitoh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8342-886X; OpenAlex author ID A5039460799. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 12

  1. Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial. Last author DOI 10.21037/hbsn-2025-315↗
  2. Concomitant Pancreatic Ductal Adenocarcinoma and Type 1 Autoimmune Pancreatitis: A Potential Issue in the Diagnosis of Carcinoma by Endoscopic Ultrasound-guide… First author DOI 10.2169/internalmedicine.0075-22↗
  3. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  4. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002032↗
  5. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. Co-author DOI 10.1016/j.pan.2021.03.007↗
  6. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer. Co-author DOI 10.1111/cas.14689↗
  7. Metachronous Pancreatic Ductal Adenocarcinoma with Adjacent Serous Cystadenoma that Was Preoperatively Diagnosed by EUS-FNA: A Case Report and Review of the Li… First author DOI 10.2169/internalmedicine.3912-19↗
  8. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal aden… Co-author DOI 10.1016/j.humpath.2018.01.009↗
  9. Case of pancreatic metastasis from colon cancer in which cell block using the Trefle® endoscopic scraper enables differential diagnosis from pancreatic cancer. First author DOI 10.4251/wjgo.v10.i3.91↗
  10. Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0670↗
  11. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0118829↗
  12. Clinical differences between mass-forming autoimmune pancreatitis and pancreatic cancer. Co-author DOI 10.3109/00365521.2012.667147↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michihiro Yoshida · 9 shared papers, 2012–2023 · strength 0.76
  2. Akihisa Kato · 8 shared papers, 2015–2023 · strength 0.73
  3. Yasuki Hori · 7 shared papers, 2015–2023 · strength 0.66
  4. Satoru Takahashi · 6 shared papers, 2017–2023 · strength 0.57
  5. Hiromi Kataoka · 5 shared papers, 2017–2023 · strength 0.55
  6. Tadahisa Inoue · 3 shared papers, 2018–2025 · strength 0.50
  7. Kenta Kachi · 3 shared papers, 2020–2023 · strength 0.37
  8. Naruomi Jinno · 3 shared papers, 2018–2021 · strength 0.29
  9. Takashi Joh · 5 shared papers, 2012–2018 · strength 0.27
  10. Yoichi Matsuo · 2 shared papers, 2020–2023 · strength 0.25
  11. Kenji Notohara · 2 shared papers, 2022–2023 · strength 0.25
  12. Kensuke Kubota · 2 shared papers, 2021–2022 · strength 0.21
  13. Tsukasa Ikeura · 2 shared papers, 2021–2022 · strength 0.21
  14. Terumi Kamisawa · 2 shared papers, 2021–2022 · strength 0.21
  15. Kazuichi Okazaki · 2 shared papers, 2021–2022 · strength 0.21
  16. Kenta Saito · 1 shared paper, 2023 · strength 0.15
  17. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
  18. Petr Dítě DrSc · 1 shared paper, 2021 · strength 0.11
  19. Tomáš Hucl · 1 shared paper, 2021 · strength 0.11
  20. Miroslav Vujasinović · 1 shared paper, 2021 · strength 0.11
  21. Peter Mačinga · 1 shared paper, 2021 · strength 0.11
  22. Marco Del Chiaro · 1 shared paper, 2021 · strength 0.11
  23. Suresh T. Chari · 1 shared paper, 2021 · strength 0.11
  24. Matthias J. Löhr · 1 shared paper, 2021 · strength 0.11
  25. Raffaele Pezzilli · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.